Inclusion Criteria:  Children ages 6 to 11 years with controlled mild nonatopic persistent physician diagnosed asthma  Non-atopic asthma: absence of a positive SPT to inhaled aeroallergens or negative specific IgE to a common regional allergen panel; historical serum IgE less than 200 IU/ml; historical serum eosinophils less than 350 cells per microliter (cells/mcL); no history of eczema; no history of allergic rhinitis; no history of food allergy Physician-diagnosed asthma: positive family history, recurrent asthma symptoms, bronchodilator responsiveness, and evidence of obstruction. Mild persistent asthma: current treatment with as-needed albuterol or low-dose ICS or daily montelukast (Step 2 therapy) Controlled asthma: Childhood Asthma Control Test score >19 Pre-bronchodilator FEV1 ≥ 80% of predicted  Exclusion Criteria:  Oral corticosteroid use in the past 6 weeks Use of ICS in combination with long-acting beta agonist or montelukast History of life-threatening asthma requiring treatment with intubation or mechanical ventilation within the past 5 years Respiratory tract infection within the past 4 weeks Any other chronic diseases or medical conditions (other than asthma) that in the opinion of the investigator would prevent participation in a trial